Peptide Therapeutics: Unveiling the Potential against Cancer-A Journey through 1989
The United States Food and Drug Administration (FDA) has approved a plethora of peptide-based drugs as effective drugs in cancer therapy. Peptides possess high specificity, permeability, target engagement, and a tolerable safety profile. They exhibit selective binding with cell surface receptors and...
Gespeichert in:
| Veröffentlicht in: | Cancers 2024-03, Vol.16 (5), p.1032 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 1032 |
| container_title | Cancers |
| container_volume | 16 |
| creator | Al Musaimi, Othman |
| description | The United States Food and Drug Administration (FDA) has approved a plethora of peptide-based drugs as effective drugs in cancer therapy. Peptides possess high specificity, permeability, target engagement, and a tolerable safety profile. They exhibit selective binding with cell surface receptors and proteins, functioning as agonists or antagonists. They also serve as imaging agents for diagnostic applications or can serve a dual-purpose as both diagnostic and therapeutic (theragnostic) agents. Therefore, they have been exploited in various forms, including linkers, peptide conjugates, and payloads. In this review, the FDA-approved prostate-specific membrane antigen (PSMA) peptide antagonists, peptide receptor radionuclide therapy (PRRT), somatostatin analogs, antibody-drug conjugates (ADCs), gonadotropin-releasing hormone (GnRH) analogs, and other peptide-based anticancer drugs are analyzed in terms of their chemical structures and properties, therapeutic targets and mechanisms of action, development journey, administration routes, and side effects. |
| doi_str_mv | 10.3390/cancers16051032 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11326481</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A786429543</galeid><sourcerecordid>A786429543</sourcerecordid><originalsourceid>FETCH-LOGICAL-c489t-42b395f01b8dbce18a1200ab1129a2f80c1eb0cfd9c8a2a5904b14dc1956cdf3</originalsourceid><addsrcrecordid>eNptkkFv3CAQhVHVqonSnHurLPXSixMGsA29VKtV06aKlEjdnhHGYy-RF7ZgR8q_L5tN0iQKHBjB994wMIR8BHrCuaKn1niLMUFNK6CcvSGHjDasrGsl3j6JD8hxStc0D86hqZv35IBL0XAu1SH5fYXbyXVYrNYYzRbnydn0tfjjb9CNzg_FtMbiKkzoJ2fGwgzG-TQVy7vU5aL4Febo8TZjMczDugAl1QfyrjdjwuP79Yiszr6vlj_Li8sf58vFRWmFVFMpWMtV1VNoZddaBGmAUWpaAKYM6yW1gC21faesNMxUiooWRGdBVbXten5Evu1tt3O7wc7mK0Yz6m10GxNvdTBOPz_xbq2HcKMBOKuFhOzw5d4hhr8zpklvXLI4jsZjmJNmOVMtxR79_AK93lWey9tRlYBG0eY_NZgRtfN9yIntzlQvGlmLjAqeqZNXqDw73DgbPPYu7z8TnO4FNoaUIvaPRQLVu1bQL1ohKz49fZtH_uHj-T8Koa8G</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2955417907</pqid></control><display><type>article</type><title>Peptide Therapeutics: Unveiling the Potential against Cancer-A Journey through 1989</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Al Musaimi, Othman</creator><creatorcontrib>Al Musaimi, Othman</creatorcontrib><description>The United States Food and Drug Administration (FDA) has approved a plethora of peptide-based drugs as effective drugs in cancer therapy. Peptides possess high specificity, permeability, target engagement, and a tolerable safety profile. They exhibit selective binding with cell surface receptors and proteins, functioning as agonists or antagonists. They also serve as imaging agents for diagnostic applications or can serve a dual-purpose as both diagnostic and therapeutic (theragnostic) agents. Therefore, they have been exploited in various forms, including linkers, peptide conjugates, and payloads. In this review, the FDA-approved prostate-specific membrane antigen (PSMA) peptide antagonists, peptide receptor radionuclide therapy (PRRT), somatostatin analogs, antibody-drug conjugates (ADCs), gonadotropin-releasing hormone (GnRH) analogs, and other peptide-based anticancer drugs are analyzed in terms of their chemical structures and properties, therapeutic targets and mechanisms of action, development journey, administration routes, and side effects.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers16051032</identifier><identifier>PMID: 38473389</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Amino acids ; Antibodies ; Antigens ; Antineoplastic drugs ; Bendamustine ; Biological products ; Cancer ; Cancer research ; Cancer therapies ; Cell surface ; Cell surface receptors ; Development and progression ; Drug approval ; Drug development ; FDA approval ; Gonadotropin-releasing hormone ; Gonadotropins ; Health aspects ; Lanreotide ; Ligands ; Oncology, Experimental ; Paracetamol ; Peptides ; Permeability ; Pharmaceutical industry ; Pharmaceuticals ; Pituitary (anterior) ; Pituitary hormones ; Prostate cancer ; Protein binding ; Proteins ; Radiation therapy ; Review ; Somatostatin ; Therapeutic targets ; Tumors ; Viral antibodies</subject><ispartof>Cancers, 2024-03, Vol.16 (5), p.1032</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the author. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c489t-42b395f01b8dbce18a1200ab1129a2f80c1eb0cfd9c8a2a5904b14dc1956cdf3</citedby><cites>FETCH-LOGICAL-c489t-42b395f01b8dbce18a1200ab1129a2f80c1eb0cfd9c8a2a5904b14dc1956cdf3</cites><orcidid>0000-0003-2421-1825</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11326481/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11326481/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38473389$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al Musaimi, Othman</creatorcontrib><title>Peptide Therapeutics: Unveiling the Potential against Cancer-A Journey through 1989</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>The United States Food and Drug Administration (FDA) has approved a plethora of peptide-based drugs as effective drugs in cancer therapy. Peptides possess high specificity, permeability, target engagement, and a tolerable safety profile. They exhibit selective binding with cell surface receptors and proteins, functioning as agonists or antagonists. They also serve as imaging agents for diagnostic applications or can serve a dual-purpose as both diagnostic and therapeutic (theragnostic) agents. Therefore, they have been exploited in various forms, including linkers, peptide conjugates, and payloads. In this review, the FDA-approved prostate-specific membrane antigen (PSMA) peptide antagonists, peptide receptor radionuclide therapy (PRRT), somatostatin analogs, antibody-drug conjugates (ADCs), gonadotropin-releasing hormone (GnRH) analogs, and other peptide-based anticancer drugs are analyzed in terms of their chemical structures and properties, therapeutic targets and mechanisms of action, development journey, administration routes, and side effects.</description><subject>Amino acids</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Antineoplastic drugs</subject><subject>Bendamustine</subject><subject>Biological products</subject><subject>Cancer</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Cell surface</subject><subject>Cell surface receptors</subject><subject>Development and progression</subject><subject>Drug approval</subject><subject>Drug development</subject><subject>FDA approval</subject><subject>Gonadotropin-releasing hormone</subject><subject>Gonadotropins</subject><subject>Health aspects</subject><subject>Lanreotide</subject><subject>Ligands</subject><subject>Oncology, Experimental</subject><subject>Paracetamol</subject><subject>Peptides</subject><subject>Permeability</subject><subject>Pharmaceutical industry</subject><subject>Pharmaceuticals</subject><subject>Pituitary (anterior)</subject><subject>Pituitary hormones</subject><subject>Prostate cancer</subject><subject>Protein binding</subject><subject>Proteins</subject><subject>Radiation therapy</subject><subject>Review</subject><subject>Somatostatin</subject><subject>Therapeutic targets</subject><subject>Tumors</subject><subject>Viral antibodies</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkkFv3CAQhVHVqonSnHurLPXSixMGsA29VKtV06aKlEjdnhHGYy-RF7ZgR8q_L5tN0iQKHBjB994wMIR8BHrCuaKn1niLMUFNK6CcvSGHjDasrGsl3j6JD8hxStc0D86hqZv35IBL0XAu1SH5fYXbyXVYrNYYzRbnydn0tfjjb9CNzg_FtMbiKkzoJ2fGwgzG-TQVy7vU5aL4Febo8TZjMczDugAl1QfyrjdjwuP79Yiszr6vlj_Li8sf58vFRWmFVFMpWMtV1VNoZddaBGmAUWpaAKYM6yW1gC21faesNMxUiooWRGdBVbXten5Evu1tt3O7wc7mK0Yz6m10GxNvdTBOPz_xbq2HcKMBOKuFhOzw5d4hhr8zpklvXLI4jsZjmJNmOVMtxR79_AK93lWey9tRlYBG0eY_NZgRtfN9yIntzlQvGlmLjAqeqZNXqDw73DgbPPYu7z8TnO4FNoaUIvaPRQLVu1bQL1ohKz49fZtH_uHj-T8Koa8G</recordid><startdate>20240302</startdate><enddate>20240302</enddate><creator>Al Musaimi, Othman</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2421-1825</orcidid></search><sort><creationdate>20240302</creationdate><title>Peptide Therapeutics: Unveiling the Potential against Cancer-A Journey through 1989</title><author>Al Musaimi, Othman</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c489t-42b395f01b8dbce18a1200ab1129a2f80c1eb0cfd9c8a2a5904b14dc1956cdf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Amino acids</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Antineoplastic drugs</topic><topic>Bendamustine</topic><topic>Biological products</topic><topic>Cancer</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Cell surface</topic><topic>Cell surface receptors</topic><topic>Development and progression</topic><topic>Drug approval</topic><topic>Drug development</topic><topic>FDA approval</topic><topic>Gonadotropin-releasing hormone</topic><topic>Gonadotropins</topic><topic>Health aspects</topic><topic>Lanreotide</topic><topic>Ligands</topic><topic>Oncology, Experimental</topic><topic>Paracetamol</topic><topic>Peptides</topic><topic>Permeability</topic><topic>Pharmaceutical industry</topic><topic>Pharmaceuticals</topic><topic>Pituitary (anterior)</topic><topic>Pituitary hormones</topic><topic>Prostate cancer</topic><topic>Protein binding</topic><topic>Proteins</topic><topic>Radiation therapy</topic><topic>Review</topic><topic>Somatostatin</topic><topic>Therapeutic targets</topic><topic>Tumors</topic><topic>Viral antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al Musaimi, Othman</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al Musaimi, Othman</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peptide Therapeutics: Unveiling the Potential against Cancer-A Journey through 1989</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2024-03-02</date><risdate>2024</risdate><volume>16</volume><issue>5</issue><spage>1032</spage><pages>1032-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>The United States Food and Drug Administration (FDA) has approved a plethora of peptide-based drugs as effective drugs in cancer therapy. Peptides possess high specificity, permeability, target engagement, and a tolerable safety profile. They exhibit selective binding with cell surface receptors and proteins, functioning as agonists or antagonists. They also serve as imaging agents for diagnostic applications or can serve a dual-purpose as both diagnostic and therapeutic (theragnostic) agents. Therefore, they have been exploited in various forms, including linkers, peptide conjugates, and payloads. In this review, the FDA-approved prostate-specific membrane antigen (PSMA) peptide antagonists, peptide receptor radionuclide therapy (PRRT), somatostatin analogs, antibody-drug conjugates (ADCs), gonadotropin-releasing hormone (GnRH) analogs, and other peptide-based anticancer drugs are analyzed in terms of their chemical structures and properties, therapeutic targets and mechanisms of action, development journey, administration routes, and side effects.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38473389</pmid><doi>10.3390/cancers16051032</doi><orcidid>https://orcid.org/0000-0003-2421-1825</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2024-03, Vol.16 (5), p.1032 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11326481 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
| subjects | Amino acids Antibodies Antigens Antineoplastic drugs Bendamustine Biological products Cancer Cancer research Cancer therapies Cell surface Cell surface receptors Development and progression Drug approval Drug development FDA approval Gonadotropin-releasing hormone Gonadotropins Health aspects Lanreotide Ligands Oncology, Experimental Paracetamol Peptides Permeability Pharmaceutical industry Pharmaceuticals Pituitary (anterior) Pituitary hormones Prostate cancer Protein binding Proteins Radiation therapy Review Somatostatin Therapeutic targets Tumors Viral antibodies |
| title | Peptide Therapeutics: Unveiling the Potential against Cancer-A Journey through 1989 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T07%3A11%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peptide%20Therapeutics:%20Unveiling%20the%20Potential%20against%20Cancer-A%20Journey%20through%201989&rft.jtitle=Cancers&rft.au=Al%20Musaimi,%20Othman&rft.date=2024-03-02&rft.volume=16&rft.issue=5&rft.spage=1032&rft.pages=1032-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers16051032&rft_dat=%3Cgale_pubme%3EA786429543%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2955417907&rft_id=info:pmid/38473389&rft_galeid=A786429543&rfr_iscdi=true |